Research Analysts Offer Predictions for ITOS FY2029 Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Stock analysts at HC Wainwright decreased their FY2029 EPS estimates for iTeos Therapeutics in a research report issued to clients and investors on Tuesday, April 29th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $1.13 per share for the year, down from their prior forecast of $1.19. HC Wainwright has a "Buy" rating and a $46.00 price target on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company cut their price target on shares of iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Wedbush reiterated an "outperform" rating and set a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. reduced their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.

iTeos Therapeutics Price Performance

ITOS stock traded down $0.46 during midday trading on Thursday, hitting $6.73. 149,362 shares of the stock traded hands, compared to its average volume of 484,942. The stock's fifty day simple moving average is $6.59 and its 200-day simple moving average is $7.50. The firm has a market cap of $257.51 million, a P/E ratio of -2.13 and a beta of 1.39. iTeos Therapeutics has a 1-year low of $4.80 and a 1-year high of $18.75.

Institutional Trading of iTeos Therapeutics

Several hedge funds have recently modified their holdings of ITOS. JPMorgan Chase & Co. grew its stake in shares of iTeos Therapeutics by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company's stock worth $4,771,000 after purchasing an additional 5,368 shares during the period. Geode Capital Management LLC increased its position in iTeos Therapeutics by 3.2% during the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company's stock worth $6,540,000 after buying an additional 20,092 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of iTeos Therapeutics by 5.0% during the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock valued at $530,000 after acquiring an additional 3,305 shares during the last quarter. Virtu Financial LLC raised its stake in iTeos Therapeutics by 84.3% in the 4th quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock valued at $142,000 after purchasing an additional 8,460 shares during the last quarter. Finally, US Bancorp DE increased its position in iTeos Therapeutics by 40.1% during the fourth quarter. US Bancorp DE now owns 16,919 shares of the company's stock worth $130,000 after purchasing an additional 4,843 shares during the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.